The efficacy and safety of nusinersen within the expanded access program in Russia
Introduction. Spinal muscular atrophy is a severe neuromuscular disease characterized by rapid progression of muscle weakness and early death. Pathogenetic therapy with nusinersen can significantly change the course of the disease and enable the patient to acquire new skills. The study of the effica...
Saved in:
| Main Authors: | S. B. Artemieva, L. M. Kuzenkova, E. S. Ilyina, Yu. A. Kursakova, L. M. Kolpakchi, E. Yu. Sapego, A. A. Golenko, S. G. Popovich, D. V. Parshin, O. A. Shidlovskaya, Yu. O. Papina, A. V. Monakhova, D. V. Vlodavets |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2020-12-01
|
| Series: | Нервно-мышечные болезни |
| Subjects: | |
| Online Access: | https://nmb.abvpress.ru/jour/article/view/396 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment
by: Yiğithan Güzin, et al.
Published: (2024-11-01) -
Nusinersen corrects L-arginine deficiency in the cerebrospinal fluid of patients with severe spinal muscular atrophy
by: Amber Hassan, et al.
Published: (2025-10-01) -
Approaches to pathogenetic therapy of spinal muscular atrophy in children and newborns
by: S. B. Artemyeva, et al.
Published: (2024-03-01) -
Experience of Nusinersen in children with proximal spinal muscular atrophy 5q in Moscow region
by: M. V. Panteleeva
Published: (2022-12-01) -
Long‐Term Effects of Nusinersen Dosing Frequency on Adult Patients With Spinal Muscular Atrophy: Efficacy of a 6‐Month Dosing Interval
by: Keita Takahashi, et al.
Published: (2025-05-01)